Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)

Capehorn, Matthew; Catarig, Andrei‐Mircea; Furberg, Julie Kjærulff; Janež, Andrej; Price, Hermione; Tadayon, Sayeh; Vergès, Bruno; Marre, Michel

doi:10.1016/j.diabet.2019.101117

Cited by 274 publications

(359 citation statements)

References 30 publications

Supporting

Mentioning

309

Contrasting

Unclassified

Order By: Relevance

“…Semaglutide is a GLP-1 analogue, with 94% amino acid homology to native GLP-1. The efficacy and safety of once-weekly subcutaneous (s.c.) administration of semaglutide has been established in the global phase 3 clinical trial programme SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes), which has included a broad range of subjects with T2D with or without background OADs or insulin [8][9][10][11][12][13][14][15][16][17].…”

Section: Key Summary Pointsmentioning

confidence: 99%

“…The number and type of background OAD therapies in subjects varied across the SUSTAIN trials and included MET (which is considered the backbone of T2D treatment and recommended as first-line therapy by most treatment guidelines) as a monotherapy or in combination with SU, one of the most common second-line therapies [3][4][5]7]. Subjects in the SUSTAIN trials remained on stable therapy, including prior background treatment, unless rescue criteria were met [8][9][10][11][12][13][14][15][16][17].…”

Section: Key Summary Pointsmentioning

confidence: 99%

“…The designs of each trial have been published previously [9][10][11]17] and are summarised in Table 1. SUSTAIN 2, 3, 4 and 10 were phase 3 multinational randomised controlled trials comparing once-weekly semaglutide (0.5 mg or 1.0 mg) with active comparators in subjects with uncontrolled T2D, defined as HbA 1c at least 7.0% to 10.0% (SUSTAIN 4), 10.5% (SUSTAIN 2 and 3) or 11.0% (in SUSTAIN 10) [9][10][11]17].…”

Section: Trial Designsmentioning

confidence: 99%

“…SU [11]; and in SUSTAIN 10, 36.6% of subjects received MET alone and 35.2% MET ? SU [17]. These groups were chosen for comparison as MET and SU are two of the most commonly prescribed OADs [19], and as guidelines recommend treatment intensification beginning with MET added to another OAD, followed by MET ?…”

Section: Subgroup Analysesmentioning

confidence: 99%

“…Exenatide ER exenatide extended release, FAS full analysis set, MET metformin, N number of subjects randomised, OAD oral antidiabetic drug, RCT randomised controlled trial, SGLT2i sodium-glucose co-transporter 2 inhibitor, SU sulphonylurea, TZD thiazolidinedione a Only subjects receiving background MET and MET ? SU were included in this analysis and TZD was not included as a background therapy in SUSTAIN 4 or SUSTAIN 10 [11,17].…”

Section: Subgroup Analysesmentioning

confidence: 99%

See 4 more Smart Citations

Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2–4 and 10

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Key Summary Pointsmentioning

confidence: 99%

Section: Key Summary Pointsmentioning

confidence: 99%

Section: Trial Designsmentioning

confidence: 99%

Section: Subgroup Analysesmentioning

confidence: 99%

Section: Subgroup Analysesmentioning

confidence: 99%

See 3 more Smart Citations

Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2–4 and 10

et al. 2020

View full text Add to dashboard Cite

show abstract

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes

Rubino

Greenway

Khalid

et al. 2022

JAMA

500

385

View full text Add to dashboard Cite

IMPORTANCE Phase 3 trials have not compared semaglutide and liraglutide, glucagon-like peptide-1 analogues available for weight management.OBJECTIVE To compare the efficacy and adverse event profiles of once-weekly subcutaneous semaglutide, 2.4 mg, vs once-daily subcutaneous liraglutide, 3.0 mg (both with diet and physical activity), in people with overweight or obesity. DESIGN, SETTING, AND PARTICIPANTS Randomized, open-label, 68-week, phase 3b trial conducted at 19 US sites from September 2019 (enrollment: September 11-November 26) to May 2021 (end of follow-up: May 11) in adults with body mass index of 30 or greater or 27 or greater with 1 or more weight-related comorbidities, without diabetes (N = 338).INTERVENTIONS Participants were randomized (3:1:3:1) to receive once-weekly subcutaneous semaglutide, 2.4 mg (16-week escalation; n = 126), or matching placebo, or once-daily subcutaneous liraglutide, 3.0 mg (4-week escalation; n = 127), or matching placebo, plus diet and physical activity. Participants unable to tolerate 2.4 mg of semaglutide could receive 1.7 mg; participants unable to tolerate 3.0 mg of liraglutide discontinued treatment and could restart the 4-week titration. Placebo groups were pooled (n = 85). MAIN OUTCOMES AND MEASURESThe primary end point was percentage change in body weight, and confirmatory secondary end points were achievement of 10% or more, 15% or more, and 20% or more weight loss, assessed for semaglutide vs liraglutide at week 68. Semaglutide vs liraglutide comparisons were open-label, with active treatment groups double-blinded against matched placebo groups. Comparisons of active treatments vs pooled placebo were supportive secondary end points. RESULTSOf 338 randomized participants (mean [SD] age, 49 [13] years; 265 women [78.4%]; mean [SD] body weight, 104.5 [23.8] kg; mean [SD] body mass index, 37.5 [6.8]), 319 (94.4%) completed the trial, and 271 (80.2%) completed treatment. The mean weight change from baseline was -15.8% with semaglutide vs -6.4% with liraglutide (difference, -9.4 percentage points [95% CI, -12.0 to -6.8]; P < .001); weight change with pooled placebo was -1.9%. Participants had significantly greater odds of achieving 10% or more, 15% or more, and 20% or more weight loss with semaglutide vs liraglutide (70.9% of participants vs 25.6% [odds ratio, 6.3 {95% CI, 3.5 to 11.2}], 55.6% vs 12.0% [odds ratio, 7.9 {95% CI, 4.1 to 15.4}], and 38.5% vs 6.0% [odds ratio, 8.2 {95% CI, 3.5 to 19.1}], respectively; all P < .001). Proportions of participants discontinuing treatment for any reason were 13.5% with semaglutide and 27.6% with liraglutide. Gastrointestinal adverse events were reported by 84.1% with semaglutide and 82.7% with liraglutide.CONCLUSIONS AND RELEVANCE Among adults with overweight or obesity without diabetes, once-weekly subcutaneous semaglutide compared with once-daily subcutaneous liraglutide, added to counseling for diet and physical activity, resulted in significantly greater weight loss at 68 weeks.

show abstract

Non‐insulin Parenteral Therapies

Vilsbøll,

Christensen,

Andersen

et al. 2024

Textbook of Diabetes

View full text Add to dashboard Cite

Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)

Cited by 274 publications

References 30 publications

Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2–4 and 10

Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2–4 and 10

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes

Non‐insulin Parenteral Therapies

Contact Info

Product

Resources

About